BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25538177)

  • 1. Low-dose aspirin use and the risk of ovarian cancer in Denmark.
    Baandrup L; Kjaer SK; Olsen JH; Dehlendorff C; Friis S
    Ann Oncol; 2015 Apr; 26(4):787-792. PubMed ID: 25538177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.
    Baandrup L
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analgesic medication use and risk of epithelial ovarian cancer in African American women.
    Peres LC; Camacho F; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy M; Cote ML; Crankshaw S; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry P; Wang F; Schildkraut JM
    Br J Cancer; 2016 Mar; 114(7):819-25. PubMed ID: 26908324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register.
    Trabert B; Aarestrup J; Ulrich LG; Wentzensen N; Sørensen TIA; Baker JL
    Gynecol Oncol; 2018 Mar; 148(3):547-552. PubMed ID: 29331371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihistamine use and risk of ovarian cancer: A population-based case-control study.
    Verdoodt F; Pottegård A; Dehlendorff C; Jäättelä M; Hallas J; Friis S; Kjaer SK
    Maturitas; 2019 Feb; 120():47-52. PubMed ID: 30583764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of nonsteroidal anti-inflammatory drugs and risk of endometrial cancer: a nationwide case-control study.
    Brøns N; Baandrup L; Dehlendorff C; Kjaer SK
    Cancer Causes Control; 2015 Jul; 26(7):973-81. PubMed ID: 25895439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of analgesic drugs and risk of ovarian cancer: results from a Danish case-control study.
    Ammundsen HB; Faber MT; Jensen A; Høgdall E; Blaakaer J; Høgdall C; Kjaer SK
    Acta Obstet Gynecol Scand; 2012 Sep; 91(9):1094-102. PubMed ID: 22646488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.
    Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Weiderpass E; Persson IR
    J Natl Cancer Inst; 2002 Apr; 94(7):497-504. PubMed ID: 11929950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiologic features of borderline ovarian tumors in California: a population-based study.
    Morris CR; Liu L; Rodriguez AO; Cress RD; Snipes K
    Cancer Causes Control; 2013 Apr; 24(4):665-74. PubMed ID: 23314731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study.
    Skriver C; Dehlendorff C; Borre M; Brasso K; Sørensen HT; Hallas J; Larsen SB; Tjønneland A; Friis S
    Cancer Causes Control; 2016 Sep; 27(9):1067-79. PubMed ID: 27503490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.
    Jung S; Allen N; Arslan AA; Baglietto L; Barricarte A; Brinton LA; Egleston BL; Falk RT; Fortner RT; Helzlsouer KJ; Gao Y; Idahl A; Kaaks R; Krogh V; Merritt MA; Lundin E; Onland-Moret NC; Rinaldi S; Schock H; Shu XO; Sluss PM; Staats PN; Sacerdote C; Travis RC; Tjønneland A; Trichopoulou A; Tworoger SS; Visvanathan K; Weiderpass E; Zeleniuch-Jacquotte A; Dorgan JF
    Int J Cancer; 2018 Jan; 142(2):262-270. PubMed ID: 28921520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.
    Kim SJ; Rosen B; Fan I; Ivanova A; McLaughlin JR; Risch H; Narod SA; Kotsopoulos J
    Br J Cancer; 2017 Mar; 116(7):964-971. PubMed ID: 28208158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.
    Merritt MA; Green AC; Nagle CM; Webb PM; ;
    Int J Cancer; 2008 Jan; 122(1):170-6. PubMed ID: 17721999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
    Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK
    Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for ovarian cancers with and without microsatellite instability.
    Segev Y; Pal T; Rosen B; McLaughlin JR; Sellers TA; Risch HA; Zhang S; Sun P; Narod SA; Schildkraut J
    Int J Gynecol Cancer; 2014 May; 24(4):664-9. PubMed ID: 24755492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
    Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
    J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for ovarian cancers with and without microsatellite instability.
    Segev Y; Pal T; Rosen B; McLaughlin JR; Sellers TA; Risch HA; Zhang S; Ping S; Narod SA; Schildkraut J
    Int J Gynecol Cancer; 2013 Jul; 23(6):1010-5. PubMed ID: 23748177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study.
    Zhou J; He ZY; Li FY; Sun JY; Lin HX; Wu SG; Chen QH
    Oncotarget; 2016 Feb; 7(7):7952-9. PubMed ID: 26788911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
    Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.